Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced positive interim data from a Phase III clinical study for its drug anlotinib. The study combines anlotinib with chemotherapy as a first-line treatment for advanced unresectable or metastatic soft-tissue sarcoma. The Independent Data Monitoring Committee (IDMC) confirmed that the primary endpoint, progression-free survival (PFS), met the predefined optimal efficacy threshold. Additionally, the secondary endpoint, overall survival (OS), showed a beneficial trend.
Anlotinib, an oral multi-target kinase inhibitor, was first approved in China in May 2018 for the treatment of advanced non-small cell lung cancer (NSCLC) that had progressed after at least two lines of systemic chemotherapy. Since then, it has received additional indications for soft tissue sarcoma, small cell lung cancer, medullary thyroid carcinoma, and differentiated thyroid carcinoma. If approved for the current indication, it would be the drug’s ninth indication, further expanding its utility in cancer treatment.
The IDMC’s positive assessment of anlotinib in the Phase III trial is a significant step forward for Sino Biopharmaceutical as it seeks to solidify its position in the global oncology market. The drug’s potential to improve progression-free survival in patients with soft-tissue sarcoma could provide a much-needed treatment option for this challenging disease.
The company’s commitment to advancing anlotinib through clinical trials reflects the ongoing innovation in China’s pharmaceutical sector. As Sino Biopharmaceutical continues to explore the drug’s potential across a range of cancer types, it also underscores the importance of collaboration and investment in research and development to bring new treatments to patients worldwide.- Flcube.com
